| Year |
Citation |
Score |
| 2024 |
Murad HY, Sabol RA, Nyiramana J, Twizeyimana A, Bortz EP, Matossian MD, Hong S, Kelly CA, Burow ME, Bunnell BA, Khismatullin DB. Mechanical Disruption by Focused Ultrasound Re-sensitizes ER+ Breast Cancer Cells to Hormone Therapy. Ultrasound in Medicine & Biology. PMID 39277462 DOI: 10.1016/j.ultrasmedbio.2024.08.015 |
0.502 |
|
| 2024 |
Rinderle CH, Baker CV, Lagarde CB, Nguyen K, Al-Ghadban S, Matossian MD, Hoang VT, Martin EC, Collins-Burow BM, Ali S, Drewry DH, Burow ME, Bunnell BA. Screening of a kinase inhibitor library identified novel targetable kinase pathways in triple-negative breast cancer. Anti-Cancer Drugs. PMID 39163320 DOI: 10.1097/CAD.0000000000001658 |
0.372 |
|
| 2024 |
Cuccia J, Ortega Quesada BA, Littlefield EP, Ham AM, Burow ME, Melvin AT, Martin EC. Loss of Hormone Receptor Expression after Exposure to Fluid Shear Stress in Breast Cancer Cell Lines. International Journal of Molecular Sciences. 25. PMID 39000231 DOI: 10.3390/ijms25137119 |
0.495 |
|
| 2024 |
Kpeli GW, Conrad KM, Bralower W, Byrne CE, Boue SM, Burow ME, Mondrinos MJ. Xenohormetic Phytochemicals Inhibit Neovascularization in Microphysiological Models of Vasculogenesis and Tumor Angiogenesis. Advanced Biology. e2300480. PMID 38831745 DOI: 10.1002/adbi.202300480 |
0.334 |
|
| 2024 |
Lagarde CB, Kavalakatt J, Benz MC, Hawes ML, Arbogast CA, Cullen NM, McConnell EC, Rinderle C, Hebert KL, Khosla M, Belgodere JA, Hoang VT, Collins-Burow BM, Bunnell BA, Burow ME, et al. Obesity-associated epigenetic alterations and the obesity-breast cancer axis. Oncogene. PMID 38310162 DOI: 10.1038/s41388-024-02954-0 |
0.335 |
|
| 2023 |
Hossain F, Ucar DA, Monticone G, Ran Y, Majumder S, Larter K, Luu H, Wyczechowska D, Heidari S, Xu K, Shanthalingam S, Matossian M, Xi Y, Burow M, Collins-Burow B, et al. Sulindac sulfide as a non-immune suppressive γ-secretase modulator to target triple-negative breast cancer. Frontiers in Immunology. 14: 1244159. PMID 37901240 DOI: 10.3389/fimmu.2023.1244159 |
0.409 |
|
| 2023 |
Dong S, Matossian MD, Yousefi H, Khosla M, Collins-Burow BM, Burow ME, Alahari SK. Targeting Mcl-1 by a small molecule NSC260594 for triple-negative breast cancer therapy. Scientific Reports. 13: 11843. PMID 37481672 DOI: 10.1038/s41598-023-37058-4 |
0.505 |
|
| 2023 |
Mukherjee D, Previs RA, Haines C, Al Abo M, Juras PK, Strickland KC, Chakraborty B, Artham S, Whitaker RS, Hebert K, Fontenot J, Patierno SR, Freedman JA, Lau FH, Burow ME, et al. Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis. Cancer Research. PMID 37335130 DOI: 10.1158/0008-5472.CAN-22-1622 |
0.402 |
|
| 2023 |
Mukherjee D, Previs RA, Haines CN, Abo MA, Juras PK, Strickland KC, Chakraborty B, Artham S, Whitaker R, Hebert KL, Fontenot J, Patierno SR, Freedman JA, Lau FH, Burow M, et al. Ca /Calmodulin Dependent Protein Kinase Kinase-2 (CaMKK2) promotes Protein Kinase G (PKG)-dependent actin cytoskeletal assembly to increase tumor metastasis. Biorxiv : the Preprint Server For Biology. PMID 37131673 DOI: 10.1101/2023.04.17.536051 |
0.389 |
|
| 2023 |
Patel JR, Banjara B, Ohemeng A, Davidson AM, Boué SM, Burow ME, Tilghman SL. Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1. Nutrients. 15. PMID 37049472 DOI: 10.3390/nu15071632 |
0.556 |
|
| 2022 |
Nguyen K, McConnell E, Edwards O, Collins-Burow BM, Burow ME. GD2+ cancer stem cells in triple-negative breast cancer: mechanisms of resistance to breast cancer therapies. Cancer Drug Resistance (Alhambra, Calif.). 5: 721-726. PMID 36176759 DOI: 10.20517/cdr.2022.30 |
0.421 |
|
| 2022 |
Bunnell BA, Martin EC, Matossian MD, Brock CK, Nguyen K, Collins-Burow B, Burow ME. The effect of obesity on adipose-derived stromal cells and adipose tissue and their impact on cancer. Cancer Metastasis Reviews. PMID 35999486 DOI: 10.1007/s10555-022-10063-1 |
0.315 |
|
| 2022 |
Dong S, Yousefi H, Savage IV, Okpechi SC, Wright MK, Matossian MD, Collins-Burow BM, Burow ME, Alahari SK. Ceritinib is a novel triple negative breast cancer therapeutic agent. Molecular Cancer. 21: 138. PMID 35768871 DOI: 10.1186/s12943-022-01601-0 |
0.476 |
|
| 2022 |
King CT, Matossian MD, Savoie JJ, Nguyen K, Wright MK, Byrne CE, Elliott S, Burks HE, Bratton MR, Pashos NC, Bunnell BA, Burow ME, Collins-Burow BM, Martin EC. Liver Kinase B1 Regulates Remodeling of the Tumor Microenvironment in Triple-Negative Breast Cancer. Frontiers in Molecular Biosciences. 9: 847505. PMID 35755802 DOI: 10.3389/fmolb.2022.847505 |
0.361 |
|
| 2022 |
Hamel K, King CT, Cavalier MB, Liimatta KQ, Rozanski GL, King TA, Lam M, Bingham GC, Byrne CE, Xing D, Collins-Burow BM, Burow ME, Belgodere JA, Bratton MR, Bunnell BA, et al. Breast Cancer-Stromal Interactions: Adipose-derived stromal/stem cell Age and Cancer Subtype Mediated Remodeling. Stem Cells and Development. PMID 35579936 DOI: 10.1089/scd.2021.0279 |
0.448 |
|
| 2022 |
Hartono AB, Kang HJ, Shi L, Phipps W, Ungerleider N, Giardina A, Chen W, Spraggon L, Somwar R, Moroz K, Drewry DH, Burow ME, Flemington E, Ladanyi M, Lee SB. Salt-Inducible Kinase 1 is a potential therapeutic target in Desmoplastic Small Round Cell Tumor. Oncogenesis. 11: 18. PMID 35443736 DOI: 10.1038/s41389-022-00395-6 |
0.314 |
|
| 2022 |
Walker RR, Patel JR, Gupta A, Davidson AM, Williams CC, Payton-Stewart F, Boué SM, Burow ME, Khupse R, Tilghman SL. Glyceollins Trigger Anti-Proliferative Effects in Hormone-Dependent Aromatase-Inhibitor-Resistant Breast Cancer Cells through the Induction of Apoptosis. International Journal of Molecular Sciences. 23. PMID 35270029 DOI: 10.3390/ijms23052887 |
0.492 |
|
| 2022 |
Cromwell EF, Sirenko O, Nikolov E, Hammer M, Brock CK, Matossian MD, Alzoubi MS, Collins-Burow BM, Burow ME. Multifunctional profiling of triple-negative breast cancer patient-derived tumoroids for disease modeling. Slas Discovery : Advancing Life Sciences R & D. PMID 35124274 DOI: 10.1016/j.slasd.2022.01.006 |
0.377 |
|
| 2022 |
Okpechi SC, Yousefi H, Nguyen K, Cheng T, Alahari NV, Collins-Burow B, Burow ME, Alahari SK. Role of Nischarin in the pathology of diseases: a special emphasis on breast cancer. Oncogene. 41: 1079-1086. PMID 35064214 DOI: 10.1038/s41388-021-02150-4 |
0.474 |
|
| 2021 |
Brock CK, Hebert KL, Artiles M, Wright MK, Cheng T, Windsor GO, Nguyen K, Alzoubi MS, Collins-Burow BM, Martin EC, Lau FH, Bunnell BA, Burow ME. A Role for Adipocytes and Adipose Stem Cells in the Breast Tumor Microenvironment and Regenerative Medicine. Frontiers in Physiology. 12: 751239. PMID 34912237 DOI: 10.3389/fphys.2021.751239 |
0.413 |
|
| 2021 |
Burks HE, Matossian MD, Rhodes LV, Phamduy T, Elliott S, Buechlein A, Rusch DB, Miller DFB, Nephew KP, Chrisey D, Collins-Burow BM, Burow ME. ZEB2 regulates endocrine therapy sensitivity and metastasis in luminal a breast cancer cells through a non-canonical mechanism. Breast Cancer Research and Treatment. PMID 34231077 DOI: 10.1007/s10549-021-06256-x |
0.797 |
|
| 2021 |
Matossian MD, Elliott S, Van Hoang T, Burks HE, Wright MK, Alzoubi MS, Yan T, Chang T, Wathieu H, Windsor GO, Hartono AB, Lee S, Zuercher WJ, Drewry DH, Wells C, ... ... Burow ME, et al. NEK5 activity regulates the mesenchymal and migratory phenotype in breast cancer cells. Breast Cancer Research and Treatment. PMID 34196902 DOI: 10.1007/s10549-021-06295-4 |
0.455 |
|
| 2021 |
Nguyen K, Rivera A, Alzoubi M, Wathieu H, Dong S, Yousefi H, Matossian M, Alahari S, Drewry D, Burow M, Collins-Burow B. Evaluation of liver kinase B1 downstream signaling expression in various breast cancers and relapse free survival after systemic chemotherapy treatment. Oncotarget. 12: 1110-1115. PMID 34084284 DOI: 10.18632/oncotarget.27929 |
0.483 |
|
| 2021 |
Matossian MD, Hoang VT, Burks HE, La J, Elliott S, Brock C, Rusch DB, Buechlein A, Nephew KP, Bhatt A, Cavanaugh JE, Flaherty PT, Collins-Burow BM, Burow ME. Constitutive activation of MEK5 promotes a mesenchymal and migratory cell phenotype in triple negative breast cancer. Oncoscience. 8: 64-71. PMID 34026925 DOI: 10.18632/oncoscience.535 |
0.549 |
|
| 2021 |
Brown LM, Hebert KL, Gurrala RR, Byrne CE, Burow M, Martin EC, Lau FH. Modeling Breast Cancer in Human Breast Tissue using a Microphysiological System. Journal of Visualized Experiments : Jove. PMID 33970144 DOI: 10.3791/62009 |
0.425 |
|
| 2021 |
Hoang VT, Matossian MD, La J, Hoang K, Ucar DA, Elliott S, Burks HE, Wright TD, Patel S, Bhatt A, Phamduy T, Chrisey D, Buechlein A, Rusch DB, Nephew KP, ... ... Burow ME, et al. Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA-1 regulation. Journal of Cellular Biochemistry. PMID 33876843 DOI: 10.1002/jcb.29916 |
0.5 |
|
| 2021 |
Byrne CE, Decombe JB, Bingham GC, Remont J, Miller LG, Khalif L, King CT, Hamel K, Bunnell BA, Burow ME, Martin EC. EVALUATION OF EXTRACELLULAR MATRIX COMPOSITION TO IMPROVE BREAST CANCER MODELING. Tissue Engineering. Part A. PMID 33797977 DOI: 10.1089/ten.TEA.2020.0364 |
0.421 |
|
| 2021 |
Gurrala R, Byrne CE, Brown LM, Tiongco RFP, Matossian MD, Savoie JJ, Collins-Burow BM, Burow ME, Martin EC, Lau FH. Quantifying Breast Cancer-Driven Fiber Alignment and Collagen Deposition in Primary Human Breast Tissue. Frontiers in Bioengineering and Biotechnology. 9: 618448. PMID 33791282 DOI: 10.3389/fbioe.2021.618448 |
0.4 |
|
| 2021 |
Matossian MD, Elliott S, Rhodes LV, Martin EC, Hoang VT, Burks HE, Zuercher WJ, Drewry DH, Collins-Burow BM, Burow ME. Application of a small molecule inhibitor screen approach to identify CXCR4 downstream signaling pathways that promote a mesenchymal and fulvestrant-resistant phenotype in breast cancer cells. Oncology Letters. 21: 380. PMID 33777204 DOI: 10.3892/ol.2021.12641 |
0.73 |
|
| 2021 |
Bhatt AB, Wright TD, Barnes V, Chakrabarty S, Matossian MD, Lexner E, Ucar DA, Miele L, Flaherty PT, Burow ME, Cavanaugh JE. Diverse and converging roles of ERK1/2 and ERK5 pathways on mesenchymal to epithelial transition in breast cancer. Translational Oncology. 14: 101046. PMID 33761370 DOI: 10.1016/j.tranon.2021.101046 |
0.551 |
|
| 2021 |
Matossian MD, Wells CI, Zuercher WJ, Collins-Burow BM, Drewry DH, Burow ME. Targeting Never-In-Mitosis-A Related Kinase 5 in Cancer: A Review. Current Medicinal Chemistry. PMID 33749548 DOI: 10.2174/0929867328666210322101749 |
0.346 |
|
| 2021 |
Bhatt AB, Patel S, Matossian MD, Ucar DA, Miele L, Burow ME, Flaherty PT, Cavanaugh JE. Molecular Mechanisms of Epithelial to Mesenchymal Transition Regulated by ERK5 Signaling. Biomolecules. 11. PMID 33572742 DOI: 10.3390/biom11020183 |
0.366 |
|
| 2020 |
Matossian MD, Giardina AA, Wright MK, Elliott S, Loch MM, Nguyen K, Zea AH, Lau FH, Moroz K, Riker AI, Jones SD, Martin EC, Bunnell BA, Miele L, Collins-Burow BM, ... Burow ME, et al. Patient-Derived Xenografts as an Innovative Surrogate Tumor Model for the Investigation of Health Disparities in Triple Negative Breast Cancer. Women's Health Reports (New Rochelle, N.Y.). 1: 383-392. PMID 33786503 DOI: 10.1089/whr.2020.0037 |
0.365 |
|
| 2020 |
Suarez-Martinez A, Sole-Gras M, Dykes SS, Wakefield ZR, Bauer K, Majbour D, Bundy A, Pampo C, Burow ME, Siemann DW, Huang Y, Murfee WL. Bioprinting on Live Tissue for Investigating Cancer Cell Dynamics. Tissue Engineering. Part A. PMID 33059528 DOI: 10.1089/ten.TEA.2020.0190 |
0.362 |
|
| 2020 |
Chang TC, Matossian MD, Elliott S, Burks HE, Sabol RA, Ucar DA, Wathieu H, Zabaleta J, Valle L, Gill S, Martin E, Riker AI, Miele L, Bunnell BA, Burow ME, et al. Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor. Plos One. 15: e0226464. PMID 33035223 DOI: 10.1371/journal.pone.0226464 |
0.508 |
|
| 2020 |
Hoang VT, Matossian MD, Ucar DA, Elliott S, La J, Wright MK, Burks HE, Perles A, Hossain F, King CT, Browning VE, Bursavich J, Fang F, Del Valle L, Bhatt AB, ... ... Burow ME, et al. ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer. Frontiers in Oncology. 10: 1164. PMID 32850332 DOI: 10.3389/Fonc.2020.01164 |
0.579 |
|
| 2020 |
Matossian MD, Burks HE, Elliott S, Hoang VT, Zuercher WJ, Wells C, Drewry DH, Kapadia N, Chang T, Yan T, Windsor GO, Nguyen K, Fang F, Nephew KP, Buechlein A, ... ... Burow ME, et al. A novel screening approach comparing kinase activity of small molecule inhibitors with similar molecular structures and distinct biologic effects in triple-negative breast cancer to identify targetable signaling pathways. Anti-Cancer Drugs. 31: 759-775. PMID 32796402 DOI: 10.1097/Cad.0000000000000962 |
0.58 |
|
| 2020 |
Alt EU, Wörner PM, Pfnür A, Ochoa JE, Schächtele DJ, Barabadi Z, Lang LM, Srivastav S, Burow ME, Chandrasekar B, Izadpanah R. Targeting TRAF3IP2, Compared to Rab27, is More Effective in Suppressing the Development and Metastasis of Breast Cancer. Scientific Reports. 10: 8834. PMID 32483202 DOI: 10.1038/S41598-020-64781-Z |
0.439 |
|
| 2020 |
Hoang VT, Matossian MD, Ucar DA, Elliott S, La J, Wright MK, Burks HE, Perles A, Hossain F, King CT, Browning VE, Bursavich J, Fang F, Del Valle L, Bhatt AB, ... ... Burow ME, et al. ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer Frontiers in Oncology. 10. DOI: 10.3389/fonc.2020.01164 |
0.435 |
|
| 2020 |
Matossian MD, Elliott S, Burks HE, Wright M, Sabol RA, Hoang VT, Ucar DA, Alfortish A, Zabaleta J, Hossain F, Chang T, Wathieu H, Pashos N, Bunnell B, Moroz K, ... ... Burow ME, et al. Abstract C110: Applications of patient-derived triple-negative breast cancer xenografts that represent understudied patients in Louisiana in targeted therapeutic research Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp18-C110 |
0.47 |
|
| 2020 |
Matossian M, Elliott S, Wright M, Chang T, Alzoubi M, Wathieu H, Sabol R, Alfortish A, Burks H, Hoang V, Ucar D, Windsor G, Yan T, Zabaleta J, Hossain F, ... ... Burow M, et al. Abstract P6-03-17: Effect of histone deacetylase inhibitors on patient-derived neoadjuvant chemotherapy resistant triple negative breast cancer xenografts that represent understudied patients Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P6-03-17 |
0.539 |
|
| 2020 |
Hossain F, Ucar DA, Majumder S, Matossian M, Monticone G, Xu K, Ran Y, Minter L, Xi Y, Burow M, Golde T, Osborne B, Miele L. Abstract P5-04-19: Sulindac sulfide as a non-immune suppressive gamma secretase modifier to target triple negative breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P5-04-19 |
0.488 |
|
| 2020 |
Wright M, Matossian M, King C, Nguyen K, Elliott S, Alzoubi M, Martin E, Collins-Burow B, Burow M. Abstract P3-01-16: Utilizing a decellularized patient-derived xenograft tumor model for the evaluation of triple negative breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P3-01-16 |
0.502 |
|
| 2020 |
Bhatt A, Wright T, Barnes V, Chakrabarty S, Flaherty P, Burow M, Cavanaugh J. Abstract 5042: Targeting the ERK5 and ERK1/2 pathways simultaneously induces mesenchymal to epithelial transition in TNBC Tumor Biology. DOI: 10.1158/1538-7445.Am2020-5042 |
0.356 |
|
| 2019 |
Wright TD, Raybuck C, Bhatt A, Monlish D, Chakrabarty S, Wendekier K, Gartland N, Gupta M, Burow ME, Flaherty PT, Cavanaugh JE. Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer. Journal of Cellular Biochemistry. PMID 31464004 DOI: 10.1002/Jcb.29350 |
0.538 |
|
| 2019 |
Bhatt AB, Gupta M, Hoang VT, Chakrabarty S, Wright TD, Elliot S, Chopra IK, Monlish D, Anna K, Burow ME, Cavanaugh JE, Flaherty PT. Novel Diphenylamine Analogs Induce Mesenchymal to Epithelial Transition in Triple Negative Breast Cancer. Frontiers in Oncology. 9: 672. PMID 31417863 DOI: 10.3389/Fonc.2019.00672 |
0.608 |
|
| 2019 |
Hasan M, Marzouk MA, Adhikari S, Wright TD, Miller BP, Matossian MD, Elliott S, Wright MK, Alzoubi MS, Collins-Burow BM, Burow ME, Holzgrabe U, Zlotos DP, Stratford RE, Witt-Enderby PA. Title: Pharmacological, mechanistic and pharmacokinetic assessment of novel melatonin-tamoxifen drug conjugates as breast cancer drugs. Molecular Pharmacology. PMID 31221824 DOI: 10.1124/Mol.119.116202 |
0.445 |
|
| 2019 |
Sabol RA, Bowles AC, Côté A, Wise R, O'Donnell B, Matossian MD, Hossain FM, Burks HE, Del Valle L, Miele L, Collins-Burow BM, Burow ME, Bunnell BA. Leptin produced by obesity-altered adipose stem cells promotes metastasis but not tumorigenesis of triple-negative breast cancer in orthotopic xenograft and patient-derived xenograft models. Breast Cancer Research : Bcr. 21: 67. PMID 31118047 DOI: 10.1186/S13058-019-1153-9 |
0.546 |
|
| 2019 |
Sabol RA, Beighley A, Giacomelli P, Wise RM, Harrison MAA, O'Donnnell BA, Sullivan BN, Lampenfeld JD, Matossian MD, Bratton MR, Wang G, Collins-Burow BM, Burow ME, Bunnell BA. Obesity-Altered Adipose Stem Cells Promote ER⁺ Breast Cancer Metastasis through Estrogen Independent Pathways. International Journal of Molecular Sciences. 20. PMID 30897853 DOI: 10.3390/Ijms20061419 |
0.57 |
|
| 2019 |
Matossian MD, Burks HE, Elliott S, Hoang VT, Bowles AC, Sabol RA, Wahba B, Anbalagan M, Rowan B, Abazeed ME, Bunnell BA, Moroz K, Miele L, Rhodes LV, Jones SD, ... ... Burow ME, et al. Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model. Bmc Cancer. 19: 205. PMID 30845999 DOI: 10.1186/S12885-019-5401-2 |
0.764 |
|
| 2019 |
Hossain F, Ucar D, Majumder S, Xu K, Ran Y, Minter L, Xi Y, Burow M, Golde T, Osborne B, Miele L. Abstract P6-22-01: Repurposing sulindac sulfide as a notch inhibitor to target cancer stem-like cells in triple negative breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P6-22-01 |
0.563 |
|
| 2019 |
Bhatt A, Wright T, Anna K, Gupta M, Chakrabarty S, Flaherty P, Hoang V, Burow M, Cavanaugh J. Abstract P5-08-07: Study of diphenylamine analogs as inducers of mesenchymal to epithelial transition in breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P5-08-07 |
0.516 |
|
| 2019 |
Ucar D, Matossian, Hoang-Barnes V, Hossain F, Gupta M, Burks H, Wright T, Cavanaugh J, Flaherty P, Burow M, Miele L. Abstract P2-03-04: A novel druggable target upstream of Notch: MEK5/ERK5 signaling regulates Jagged-1 and Notch1 expression in triple negative breast cancer stem cells Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P2-03-04 |
0.596 |
|
| 2019 |
Yan TJ, Burow ME, Martin EC. Abstract 4236: Evaluating alterations in mRNA biogenesis with TCGA breast cancer sequencing data Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-4236 |
0.477 |
|
| 2019 |
Hossain F, Ucar DA, Majumder S, Matossian M, Xu K, Ran Y, Minter L, Xi Y, Burow M, Golde T, Osborne B, Miele L. Abstract 3439: Sulindac sulfide as a gamma secretase modifier to target triple negative breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3439 |
0.523 |
|
| 2019 |
Bhatt AB, Wright TD, Anna K, Gupta M, Chakrabarty S, Hoang V, Burow M, Flaherty PT, Cavanaugh JE. Abstract 1879: Novel diphenylamine analogs induce mesenchymal to epithelial transition and enhance the sensitivity of breast cancer cells to conventional chemotherapeutic agents Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-1879 |
0.543 |
|
| 2019 |
Coward J, Matossian MD, Roberts PA, Johnson J, Burow ME, Lemieux KP. Abstract 4605: Exosomes harvested from patient-derived-explants or cells-enhance proliferation and migration in TNBC breast cancer cells and breast epithelial cells Cancer Research. 79: 4605-4605. DOI: 10.1158/1538-7445.Am2019-4605 |
0.582 |
|
| 2019 |
Sinha SK, Brown H, Loftus A, Matossian MD, Collins-Burow BM, Burow ME. Abstract 1077: Development of a qPCR cfDNA analysis method for the assessment of tumor burden and metastatic status in live PDX mice Cancer Research. 79: 1077-1077. DOI: 10.1158/1538-7445.Am2019-1077 |
0.317 |
|
| 2019 |
Bhatt AB, Wright TD, Patel S, Chakrabarty S, Barnes V, Burow M, Flaherty PT, Cavanaugh J. Abstract B078: Inhibition of the MAPK pathways enhances the sensitivity of triple negative breast cancer cells to chemotherapeutic drugs Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B078 |
0.581 |
|
| 2018 |
Penrose HM, Cable C, Heller S, Ungerleider N, Nakhoul H, Baddoo M, Hartono AB, Lee SB, Burow ME, Flemington EF, Crawford SE, Savkovic SD. Loss of Forkhead Box O3 Facilitates Inflammatory Colon Cancer: Transcriptome Profiling of the Immune Landscape and Novel Targets. Cellular and Molecular Gastroenterology and Hepatology. 7: 391-408. PMID 30718226 DOI: 10.1016/J.Jcmgh.2018.10.003 |
0.354 |
|
| 2018 |
Hossain F, Sorrentino C, Ucar DA, Peng Y, Matossian M, Wyczechowska D, Crabtree J, Zabaleta J, Morello S, Del Valle L, Burow M, Collins-Burow B, Pannuti A, Minter LM, Golde TE, et al. Notch Signaling Regulates Mitochondrial Metabolism and NF-κB Activity in Triple-Negative Breast Cancer Cells via IKKα-Dependent Non-canonical Pathways. Frontiers in Oncology. 8: 575. PMID 30564555 DOI: 10.3389/Fonc.2018.00575 |
0.501 |
|
| 2018 |
Belgodere JA, King CT, Bursavich JB, Burow ME, Martin EC, Jung JP. Engineering Breast Cancer Microenvironments and 3D Bioprinting. Frontiers in Bioengineering and Biotechnology. 6: 66. PMID 29881724 DOI: 10.3389/Fbioe.2018.00066 |
0.516 |
|
| 2018 |
Matossian MD, Burks HE, Elliott S, Hoang VT, Bowles AC, Sabol RA, Bunnell BA, Martin EC, Burow ME, Collins-Burow BM. Panobinostat suppresses the mesenchymal phenotype in a novel claudin-low triple negative patient-derived breast cancer model. Oncoscience. 5: 99-108. PMID 29854878 DOI: 10.18632/oncoscience.412 |
0.409 |
|
| 2018 |
Chakrabarty S, Monlish DA, Gupta M, Wright TD, Hoang VT, Fedak M, Chopra I, Flaherty PT, Madura J, Mannepelli S, Burow ME, Cavanaugh JE. Structure activity relationships of anthranilic acid-based compounds on cellular and in vivo mitogen activated protein kinase-5 signaling pathways. Bioorganic & Medicinal Chemistry Letters. PMID 29803729 DOI: 10.1016/J.Bmcl.2018.05.029 |
0.301 |
|
| 2018 |
Guo S, Zhang C, Bratton M, Mottamal M, Liu J, Ma P, Zheng S, Zhong Q, Yang L, Wiese TE, Wu Y, Ellis MJ, Matossian M, Burow ME, Miele L, et al. ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models. Oncotarget. 9: 6924-6937. PMID 29467940 DOI: 10.18632/Oncotarget.24023 |
0.449 |
|
| 2018 |
Matossian MD, Burks HE, Bowles AC, Elliott S, Hoang VT, Sabol RA, Pashos NC, O'Donnell B, Miller KS, Wahba BM, Bunnell BA, Moroz K, Zea AH, Jones SD, Ochoa AC, ... ... Burow ME, et al. A novel patient-derived xenograft model for claudin-low triple-negative breast cancer. Breast Cancer Research and Treatment. PMID 29392581 DOI: 10.1007/S10549-018-4685-2 |
0.777 |
|
| 2018 |
Matossian M, Burks H, Chang T, Bowles A, Sabol R, Hoang V, Bunnell B, Alfortish A, Moroz K, Zea A, Riker A, Jones S, Bilyeu ADU, Hossain F, Miller K, ... ... Burow M, et al. Abstract A01: Application of patient-derived models from understudied patient populations to discover therapeutically targetable pathways in triple-negative breast cancer systems Molecular Cancer Research. 16. DOI: 10.1158/1557-3125.Advbc17-A01 |
0.553 |
|
| 2018 |
Hossain F, Sorrentino C, Bilyeu AU, Matossian M, Crabtree J, Pannuti A, Burow M, Golde T, Osborne B, Miele L. Abstract P6-07-06: Targeting cancer stem-like cells metabolism via non-canonical notch signaling pathways in triple negative breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P6-07-06 |
0.58 |
|
| 2018 |
Matossian M, Burks H, Bowles A, Sabol R, Hoang V, Elliott S, Bunnell B, Zuercher W, Drewry D, Wells C, Alfortish A, Lee S, Hartono A, Jones S, Moroz K, ... ... Burow M, et al. Abstract P5-05-05: Patient-derived triple negative breast cancer xenografts as a translational model to screen for novel kinase pathways Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P5-05-05 |
0.501 |
|
| 2018 |
Ucar-Bilyeu DA, Matossian MD, Barnes VH, Hossain FM, Gupta M, Burks HE, Wright TD, Cavanaugh J, Flaherty P, Burow ME, Miele L. Abstract 967: Targeting notch one notch above Cancer Research. 78: 967-967. DOI: 10.1158/1538-7445.Am2018-967 |
0.54 |
|
| 2018 |
Bhatt AB, Wright TD, Anna K, Gupta M, Flaherty P, Hoang V, Burow M, Cavanaugh JE. Abstract 4204: Structure-activity relationship of diphenylamine derivatives to target epithelial to mesenchymal transition in triple negative breast cancer Tumor Biology. DOI: 10.1158/1538-7445.Am2018-4204 |
0.516 |
|
| 2018 |
Wright TD, Raybuck C, Gartland N, Wendekier K, Monlish D, Chakrabarty S, Flaherty PT, Burow ME, Cavanaugh JE. Abstract 2392: Evaluation of synergistic PI3K/Akt and MEK5/ERK5 inhibition in triple-negative breast cancer Cancer Research. 78: 2392-2392. DOI: 10.1158/1538-7445.Am2018-2392 |
0.561 |
|
| 2018 |
Hossain F, Bilyeu ADU, Sorrentino C, Crabtree J, Pannuti A, Matossian M, Burow M, Golde T, Osborne B, Miele L. Abstract 157: Targeting cancer stem-like cells in triple negative breast cancer Cancer Research. 78: 157-157. DOI: 10.1158/1538-7445.Am2018-157 |
0.604 |
|
| 2018 |
Sabol R, Murad H, Burow M, Khismatullin D, Bunnell B. 2070 High-intensity focused ultrasound (HIFU) can be used synergistically with tamoxifen to overcome resistance in preclinical and patient derived xenograft models Journal of Clinical and Translational Science. 2: 14-14. DOI: 10.1017/cts.2018.80 |
0.403 |
|
| 2018 |
Bunnell B, Sabol R, Strong A, Burow M. Obesity-altered adipose stem cells promote breast cancer progression and metastasis Cytotherapy. 20: S30. DOI: 10.1016/J.Jcyt.2018.02.075 |
0.493 |
|
| 2017 |
Strong AL, Pei DT, Hurst CG, Gimble JM, Burow ME, Bunnell BA. Obesity Enhances the Conversion of Adipose-Derived Stromal/Stem Cells into Carcinoma-Associated Fibroblast Leading to Cancer Cell Proliferation and Progression to an Invasive Phenotype. Stem Cells International. 2017: 9216502. PMID 29527228 DOI: 10.1155/2017/9216502 |
0.494 |
|
| 2017 |
Zhou W, Guo S, Liu M, Burow M, Wang G. Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy. Current Medicinal Chemistry. PMID 28875842 DOI: 10.2174/0929867324666170830111531 |
0.443 |
|
| 2017 |
Matossian MD, Elliott S, Hoang VT, Burks HE, Phamduy TB, Chrisey DB, Zuercher WJ, Drewry DH, Wells C, Collins-Burow B, Burow ME. Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes. Plos One. 12: e0177802. PMID 28771473 DOI: 10.1371/Journal.Pone.0177802 |
0.481 |
|
| 2017 |
Anbalagan M, Sheng M, Fleischer B, Zhang Y, Gao Y, Hoang VT, Matossian MD, Burks HE, Burow ME, Collins-Burow BM, Hangauer D, Rowan BG. Dual Src Kinase/Pretubulin Inhibitor, KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen Through ERα Re-expression. Molecular Cancer Research : McR. PMID 28751463 DOI: 10.1158/1541-7786.Mcr-16-0297-T |
0.56 |
|
| 2017 |
Vinson BT, Phamduy T, Shipman J, Riggs B, Strong A, Murfee W, Burow M, Bunnell B, Sklare S, Huang Y, Chrisey D. Laser direct-write based fabrication of a spatially-defined, biomimetic construct as a potential model for breast cancer cell invasion into adipose tissue. Biofabrication. PMID 28382922 DOI: 10.1088/1758-5090/Aa6Bad |
0.529 |
|
| 2017 |
Hoang VT, Yan TJ, Cavanaugh JE, Flaherty PT, Beckman BS, Burow ME. MEK5-ERK5 Signaling in Cancer: Implications for Targeted Therapy. Cancer Letters. PMID 28153789 DOI: 10.1016/J.Canlet.2017.01.034 |
0.485 |
|
| 2017 |
Burks HE, Elliott S, Hoang VT, Matossian MD, Burow BC, Burow ME. Abstract 5079: Inhibition of HDAC2, but not HDAC1, abrogates triple negative breast cancer progression and metastasis Cancer Research. 77: 5079-5079. DOI: 10.1158/1538-7445.Am2017-5079 |
0.572 |
|
| 2017 |
Matossian MD, Burks HE, Bowles AC, Sabol RA, Hoang VT, Bunnell B, Zuercher WJ, Drewry DH, Wells C, Moroz K, Burow ME, Collins-Burow B. Abstract 1117: Triple negative breast cancer patient-derived xenografts as a translational model for discovery of novel therapeutic targets Cancer Research. 77: 1117-1117. DOI: 10.1158/1538-7445.Am2017-1117 |
0.523 |
|
| 2016 |
Conger AK, Martin EC, Yan TJ, Rhodes LV, Hoang VT, La J, Anbalagan M, Burks HE, Rowan BG, Nephew KP, Collins-Burow BM, Burow ME. Argonaute 2 Expression Correlates with a Luminal B Breast Cancer Subtype and Induces Estrogen Receptor Alpha Isoform Variation. Non-Coding Rna. 2. PMID 29657266 DOI: 10.3390/Ncrna2030008 |
0.801 |
|
| 2016 |
Burks H, Pashos N, Martin E, Mclachlan J, Bunnell B, Burow M. Endocrine disruptors and the tumor microenvironment: A new paradigm in breast cancer biology. Molecular and Cellular Endocrinology. PMID 28012841 DOI: 10.1016/J.Mce.2016.12.010 |
0.606 |
|
| 2016 |
Martin EC, Conger AK, Yan TJ, Hoang VT, Miller DF, Buechlein A, Rusch DB, Nephew KP, Collins-Burow BM, Burow ME. MicroRNA-335-5p and -3p Synergize to Inhibit Estrogen Receptor Alpha Expression and Promote Tamoxifen Resistance. Febs Letters. PMID 28008602 DOI: 10.1002/1873-3468.12538 |
0.475 |
|
| 2016 |
Li M, Li X, Zhuang Y, Wang Y, Burow ME, Collins-Burow B, Xue M, Song C, Shan B. Induction of HOXA9 expression in three-dimensional organotypic culture of the Claudin-low breast cancer cells. Oncotarget. PMID 27409175 DOI: 10.18632/Oncotarget.10491 |
0.52 |
|
| 2016 |
Burks HE, Phamduy TB, Azimi MS, Saksena J, Burow ME, Collins-Burow BM, Chrisey DB, Murfee WL. Laser Direct-Write onto Live Tissues: A Novel Model for Studying Cancer Cell Migration. Journal of Cellular Physiology. PMID 26923437 DOI: 10.1002/Jcp.25363 |
0.435 |
|
| 2016 |
Matossian MD, Elliott S, Hoang VT, Burks HE, Phamudy TB, Chrisey D, Zuercher WJ, Drewry DH, Wells C, Collins-Burow B, Burow ME. Abstract 684: Targeting an unconventional kinase-invasion axis in breast cancer metastasis Cancer Research. 76: 684-684. DOI: 10.1158/1538-7445.Am2016-684 |
0.571 |
|
| 2016 |
Martin E, Pashos N, Gimble J, Bunnell B, Burow M, Collins-Burow B. Abstract 5096: Development of a decellularized tumor model for the evaluation of breast carcinomas Cancer Research. 76: 5096-5096. DOI: 10.1158/1538-7445.Am2016-5096 |
0.573 |
|
| 2016 |
Burks HE, Rhodes LV, Martin EC, Hoang VT, Elliott S, Badoo M, Phamduy T, Buechlein A, Rusch D, Chrisey D, Flemington E, Nephew K, Collins-Burow B, Burow ME. Abstract 4410: ZEB2 drives cell motility and metastasis in ER+ breast cancer cells through a novel, E-cadherin independent pathway Cancer Research. 76: 4410-4410. DOI: 10.1158/1538-7445.Am2016-4410 |
0.818 |
|
| 2016 |
Hoang VT, Elliott S, Martin EC, Rhodes LV, Burks HE, Matossian M, Chakrabarty S, Monlish D, Phamduy TB, Curley L, Anbalagan M, Rowan BG, Chrisey D, Cavanaugh JE, Flaherty PT, ... ... Burow ME, et al. Abstract 1596: Induction of mesenchymal-to-epithelial transition through pan-MEK inhibition in triple-negative breast cancer Cancer Research. 76: 1596-1596. DOI: 10.1158/1538-7445.Am2016-1596 |
0.81 |
|
| 2016 |
Flaherty PT, Shah D, Gupta M, Wright T, Cavanaugh JE, Burow ME. Abstract 1337: Exploration of 2-aryl fused thiophene analogs as selective inhibitors of MEK5 Cancer Research. 76: 1337-1337. DOI: 10.1158/1538-7445.Am2016-1337 |
0.461 |
|
| 2015 |
Carriere PP, Llopis SD, Naiki AC, Nguyen G, Phan T, Nguyen MM, Preyan LC, Yearby L, Pratt J, Burks H, Davenport IR, Nguyen TA, Parker-Lemieux K, Payton-Stewart F, Williams CC, ... ... Burow ME, et al. Glyceollin I Reverses Epithelial to Mesenchymal Transition in Letrozole Resistant Breast Cancer through ZEB1. International Journal of Environmental Research and Public Health. 13. PMID 26703648 DOI: 10.3390/Ijerph13010010 |
0.568 |
|
| 2015 |
Rhodes LV, Tate CR, Hoang VT, Burks HE, Gilliam D, Martin EC, Elliott S, Miller DB, Buechlein A, Rusch D, Tang H, Nephew KP, Burow ME, Collins-Burow BM. Regulation of triple-negative breast cancer cell metastasis by the tumor-suppressor liver kinase B1. Oncogenesis. 4: e168. PMID 26436950 DOI: 10.1038/oncsis.2015.27 |
0.805 |
|
| 2015 |
Strong AL, Ohlstein JF, Biagas BA, Rhodes LV, Pei DT, Tucker HA, Llamas C, Bowles AC, Dutreil MF, Zhang S, Gimble JM, Burow ME, Bunnell BA. Leptin produced by obese adipose stromal/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers. Breast Cancer Research : Bcr. 17: 112. PMID 26286584 DOI: 10.1186/S13058-015-0622-Z |
0.757 |
|
| 2015 |
Phamduy TB, Sweat RS, Azimi MS, Burow ME, Murfee WL, Chrisey DB. Printing cancer cells into intact microvascular networks: a model for investigating cancer cell dynamics during angiogenesis. Integrative Biology : Quantitative Biosciences From Nano to Macro. 7: 1068-78. PMID 26190039 DOI: 10.1039/C5Ib00151J |
0.456 |
|
| 2015 |
Rhodes LV, Martin EC, Segar HC, Miller DF, Buechlein A, Rusch DB, Nephew KP, Burow ME, Collins-Burow BM. Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer. Oncotarget. 6: 16638-52. PMID 26062653 DOI: 10.18632/Oncotarget.3184 |
0.723 |
|
| 2015 |
Bamji SF, Page RB, Patel D, Sanders A, Alvarez AR, Gambrell C, Naik K, Raghavan AM, Burow ME, Boue SM, Klinge CM, Ivanova M, Corbitt C. Soy glyceollins regulate transcript abundance in the female mouse brain. Functional & Integrative Genomics. PMID 25953511 DOI: 10.1007/S10142-015-0442-3 |
0.421 |
|
| 2015 |
Bratton MR, Martin EC, Elliott S, Rhodes LV, Collins-Burow BM, McLachlan JA, Wiese TE, Boue SM, Burow ME. Glyceollin, a novel regulator of mTOR/p70S6 in estrogen receptor positive breast cancer. The Journal of Steroid Biochemistry and Molecular Biology. 150: 17-23. PMID 25771071 DOI: 10.1016/J.Jsbmb.2014.12.014 |
0.792 |
|
| 2015 |
Strong AL, Burow ME, Gimble JM, Bunnell BA. Concise review: The obesity cancer paradigm: exploration of the interactions and crosstalk with adipose stem cells. Stem Cells (Dayton, Ohio). 33: 318-26. PMID 25267443 DOI: 10.1002/Stem.1857 |
0.375 |
|
| 2014 |
Martin EC, Krebs AE, Burks HE, Elliott S, Baddoo M, Collins-Burow BM, Flemington EK, Burow ME. miR-155 induced transcriptome changes in the MCF-7 breast cancer cell line leads to enhanced mitogen activated protein kinase signaling. Genes & Cancer. 5: 353-64. PMID 25352952 DOI: 10.18632/Genesandcancer.33 |
0.398 |
|
| 2014 |
Zhuang Y, Nguyen HT, Burow ME, Zhuo Y, El-Dahr SS, Yao X, Cao S, Flemington EK, Nephew KP, Fang F, Collins-Burow B, Rhodes LV, Yu Q, Jayawickramarajah J, Shan B. Elevated expression of long intergenic non-coding RNA HOTAIR in a basal-like variant of MCF-7 breast cancer cells. Molecular Carcinogenesis. PMID 25328122 DOI: 10.1002/Mc.22237 |
0.791 |
|
| 2014 |
Martin EC, Rhodes LV, Elliott S, Krebs AE, Nephew KP, Flemington EK, Collins-Burow BM, Burow ME. microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity. Molecular Cancer. 13: 229. PMID 25283550 DOI: 10.1186/1476-4598-13-229 |
0.767 |
|
| 2014 |
Strong AL, Ohlstein JF, Jiang Q, Zhang Q, Zheng S, Boue SM, Elliott S, Gimble JM, Burow ME, Wang G, Bunnell BA. Novel daidzein analogs enhance osteogenic activity of bone marrow-derived mesenchymal stem cells and adipose-derived stromal/stem cells through estrogen receptor dependent and independent mechanisms. Stem Cell Research & Therapy. 5: 105. PMID 25168698 DOI: 10.1186/Scrt493 |
0.304 |
|
| 2014 |
Ohlstein JF, Strong AL, McLachlan JA, Gimble JM, Burow ME, Bunnell BA. Bisphenol A enhances adipogenic differentiation of human adipose stromal/stem cells. Journal of Molecular Endocrinology. 53: 345-53. PMID 25143472 DOI: 10.1530/Jme-14-0052 |
0.39 |
|
| 2014 |
Gestaut MM, Antoon JW, Burow ME, Beckman BS. Inhibition of sphingosine kinase-2 ablates androgen resistant prostate cancer proliferation and survival. Pharmacological Reports : Pr. 66: 174-8. PMID 24905325 DOI: 10.1016/J.Pharep.2013.08.014 |
0.352 |
|
| 2014 |
Strong AL, Jiang Q, Zhang Q, Zheng S, Boue SM, Elliott S, Burow ME, Bunnell BA, Wang G. Design, synthesis, and osteogenic activity of daidzein analogs on human mesenchymal stem cells. Acs Medicinal Chemistry Letters. 5: 143-8. PMID 24900787 DOI: 10.1021/Ml400397K |
0.402 |
|
| 2014 |
Rhodes LV, Tate CR, Segar HC, Burks HE, Phamduy TB, Hoang V, Elliott S, Gilliam D, Pounder FN, Anbalagan M, Chrisey DB, Rowan BG, Burow ME, Collins-Burow BM. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Breast Cancer Research and Treatment. 145: 593-604. PMID 24810497 DOI: 10.1007/S10549-014-2979-6 |
0.803 |
|
| 2014 |
Martin EC, Elliott S, Rhodes LV, Antoon JW, Fewell C, Zhu Y, Driver JL, Jodari-Karimi M, Taylor CW, Flemington EK, Beckman BS, Collins-Burow BM, Burow ME. Preferential star strand biogenesis of pre-miR-24-2 targets PKC-alpha and suppresses cell survival in MCF-7 breast cancer cells. Molecular Carcinogenesis. 53: 38-48. PMID 22911661 DOI: 10.1002/Mc.21946 |
0.721 |
|
| 2014 |
Rhodes LV, Tate CR, Burks HE, Hoang VT, Gilliam D, Martin EC, Elliott S, Miller DF, Buechlein A, Rusch D, Tang H, Nephew KP, Burow ME, Collins-Burow BM. Abstract 1571: The tumor suppressor Liver Kinase B1 inhibits triple-negative breast cancer cell metastasis via regulation of AP-1 signaling Cancer Research. 74: 1571-1571. DOI: 10.1158/1538-7445.Am2014-1571 |
0.818 |
|
| 2014 |
Hoang VT, Elliott S, Martin EC, Rhodes LV, Segar HC, Burks H, Chakrabarty S, Monlish D, Phamduy TB, Chrisey D, Cavanaugh JE, Flaherty P, Collins-Burow BM, Burow ME. Abstract 1052: Dual role of MEK1/2 and MEK5 in the reversal of epithelial-to-mesenchymal transition Cancer Research. 74: 1052-1052. DOI: 10.1158/1538-7445.Am2014-1052 |
0.803 |
|
| 2014 |
Burks HE, Rhodes L, Martin E, Phamduy T, Elliot S, Hoang V, Segar H, Buechlein A, Rusch D, Miller D, Baddoo M, Flemington E, Nephew K, Chrisey D, Collins-Burow B, ... Burow M, et al. Abstract 1034: ZEB2 promotes cell motility and metastasis in ER+ breast cancer cells Cancer Research. 74: 1034-1034. DOI: 10.1158/1538-7445.Am2014-1034 |
0.798 |
|
| 2013 |
Strong AL, Strong TA, Rhodes LV, Semon JA, Zhang X, Shi Z, Zhang S, Gimble JM, Burow ME, Bunnell BA. Obesity associated alterations in the biology of adipose stem cells mediate enhanced tumorigenesis by estrogen dependent pathways. Breast Cancer Research : Bcr. 15: R102. PMID 24176089 DOI: 10.1186/Bcr3569 |
0.762 |
|
| 2013 |
Antoon JW, Martin EC, Lai R, Salvo VA, Tang Y, Nitzchke AM, Elliott S, Nam SY, Xiong W, Rhodes LV, Collins-Burow B, David O, Wang G, Shan B, Beckman BS, ... ... Burow ME, et al. MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis. Plos One. 8: e69291. PMID 23950888 DOI: 10.1371/Journal.Pone.0069291 |
0.818 |
|
| 2013 |
Struckhoff AP, Rana MK, Kher SS, Burow ME, Hagan JL, Del Valle L, Worthylake RA. PDZ-RhoGEF is essential for CXCR4-driven breast tumor cell motility through spatial regulation of RhoA. Journal of Cell Science. 126: 4514-26. PMID 23868972 DOI: 10.1242/Jcs.132381 |
0.527 |
|
| 2013 |
Strong MJ, Xu G, Coco J, Baribault C, Vinay DS, Lacey MR, Strong AL, Lehman TA, Seddon MB, Lin Z, Concha M, Baddoo M, Ferris M, Swan KF, Sullivan DE, ... Burow ME, et al. Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy. Plos Pathogens. 9: e1003341. PMID 23671415 DOI: 10.1371/Journal.Ppat.1003341 |
0.316 |
|
| 2013 |
Miller DF, Yan PS, Buechlein A, Rodriguez BA, Yilmaz AS, Goel S, Lin H, Collins-Burow B, Rhodes LV, Braun C, Pradeep S, Rupaimoole R, Dalkilic M, Sood AK, Burow ME, et al. A new method for stranded whole transcriptome RNA-seq. Methods (San Diego, Calif.). 63: 126-34. PMID 23557989 DOI: 10.1016/J.Ymeth.2013.03.023 |
0.635 |
|
| 2013 |
Zheng S, Zhong Q, Jiang Q, Mottamal M, Zhang Q, Zhu N, Burow ME, Worthylake RA, Wang G. Discovery of a Series of Thiazole Derivatives as Novel Inhibitors of Metastatic Cancer Cell Migration and Invasion. Acs Medicinal Chemistry Letters. 4: 191-196. PMID 23526571 DOI: 10.1021/Ml300322N |
0.43 |
|
| 2013 |
Antoon JW, Nitzchke AM, Martin EC, Rhodes LV, Nam S, Wadsworth S, Salvo VA, Elliott S, Collins-Burow B, Nephew KP, Burow ME. Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition. International Journal of Oncology. 42: 1139-50. PMID 23403951 DOI: 10.3892/Ijo.2013.1814 |
0.76 |
|
| 2013 |
Johnson KP, Yearby LA, Stoute D, Burow ME, Rhodes LV, Gray M, Carriere P, Tilghman SL, McLachlan JA, Ochieng J. In vitro and in vivo evaluation of novel anticancer agents in triple negative breast cancer models. Journal of Health Care For the Poor and Underserved. 24: 104-11. PMID 23395947 DOI: 10.1353/Hpu.2013.0047 |
0.78 |
|
| 2013 |
Tilghman SL, Rhodes LV, Bratton MR, Carriere P, Preyan LC, Boue SM, Vasaitis TS, McLachlan JA, Burow ME. Phytoalexins, miRNAs and breast cancer: a review of phytochemical-mediated miRNA regulation in breast cancer. Journal of Health Care For the Poor and Underserved. 24: 36-46. PMID 23395943 DOI: 10.1353/Hpu.2013.0036 |
0.752 |
|
| 2013 |
Phamduy TB, Rhodes LV, Burow ME, Chrisey DB. Abstract A016: Electrical impedance assessment of the effect of LBH589 on the cellular behavior and migratory potential of breast cancer cells Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-A016 |
0.75 |
|
| 2012 |
Martin EC, Bratton MR, Zhu Y, Rhodes LV, Tilghman SL, Collins-Burow BM, Burow ME. Insulin-like growth factor-1 signaling regulates miRNA expression in MCF-7 breast cancer cell line. Plos One. 7: e49067. PMID 23226206 DOI: 10.1371/Journal.Pone.0049067 |
0.768 |
|
| 2012 |
Antoon JW, Bratton MR, Guillot LM, Wadsworth S, Salvo VA, Elliott S, McLachlan JA, Burow ME. Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinase. American Journal of Cancer Research. 2: 446-58. PMID 22860234 |
0.37 |
|
| 2012 |
Antoon JW, White MD, Driver JL, Burow ME, Beckman BS. Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer. Experimental Biology and Medicine (Maywood, N.J.). 237: 832-44. PMID 22859737 DOI: 10.1258/Ebm.2012.012028 |
0.596 |
|
| 2012 |
Antoon JW, Lai R, Struckhoff AP, Nitschke AM, Elliott S, Martin EC, Rhodes LV, Yoon NS, Salvo VA, Shan B, Beckman BS, Nephew KP, Burow ME. Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance. Scientific Reports. 2: 539. PMID 22844580 DOI: 10.1038/Srep00539 |
0.765 |
|
| 2012 |
Antoon JW, Bratton MR, Guillot LM, Wadsworth S, Salvo VA, Burow ME. Inhibition of p38-MAPK alters SRC coactivation and estrogen receptor phosphorylation. Cancer Biology & Therapy. 13: 1026-33. PMID 22825349 DOI: 10.4161/Cbt.20992 |
0.587 |
|
| 2012 |
Rhodes LV, Tilghman SL, Boue SM, Wang S, Khalili H, Muir SE, Bratton MR, Zhang Q, Wang G, Burow ME, Collins-Burow BM. Glyceollins as novel targeted therapeutic for the treatment of triple-negative breast cancer. Oncology Letters. 3: 163-171. PMID 22740874 DOI: 10.3892/Ol.2011.460 |
0.798 |
|
| 2012 |
Collins-Burow BM, Antoon JW, Frigo DE, Elliott S, Weldon CB, Boue SM, Beckman BS, Curiel TJ, Alam J, McLachlan JA, Burow ME. Antiestrogenic activity of flavonoid phytochemicals mediated via the c-Jun N-terminal protein kinase pathway. Cell-type specific regulation of estrogen receptor alpha. The Journal of Steroid Biochemistry and Molecular Biology. 132: 186-93. PMID 22634477 DOI: 10.1016/J.Jsbmb.2012.05.004 |
0.504 |
|
| 2012 |
Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME, Collins-Burow BM. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Research : Bcr. 14: R79. PMID 22613095 DOI: 10.1186/Bcr3192 |
0.794 |
|
| 2012 |
Bratton MR, Frigo DE, Segar HC, Nephew KP, McLachlan JA, Wiese TE, Burow ME. The organochlorine o,p'-DDT plays a role in coactivator-mediated MAPK crosstalk in MCF-7 breast cancer cells. Environmental Health Perspectives. 120: 1291-6. PMID 22609851 DOI: 10.1289/Ehp.1104296 |
0.5 |
|
| 2012 |
Nguyen HT, Li C, Lin Z, Zhuang Y, Flemington EK, Burow ME, Lin Y, Shan B. The microRNA expression associated with morphogenesis of breast cancer cells in three-dimensional organotypic culture. Oncology Reports. 28: 117-26. PMID 22576799 DOI: 10.3892/Or.2012.1764 |
0.372 |
|
| 2012 |
Bratton MR, Antoon JW, Duong BN, Frigo DE, Tilghman S, Collins-Burow BM, Elliott S, Tang Y, Melnik LI, Lai L, Alam J, Beckman BS, Hill SM, Rowan BG, McLachlan JA, ... Burow ME, et al. Gαo potentiates estrogen receptor α activity via the ERK signaling pathway. The Journal of Endocrinology. 214: 45-54. PMID 22562654 DOI: 10.1530/Joe-12-0097 |
0.436 |
|
| 2012 |
Antoon JW, White MD, Burow ME, Beckman BS. Dual inhibition of sphingosine kinase isoforms ablates TNF-induced drug resistance. Oncology Reports. 27: 1779-86. PMID 22469881 DOI: 10.3892/Or.2012.1743 |
0.513 |
|
| 2012 |
Zhou C, Zhong Q, Rhodes LV, Townley I, Bratton MR, Zhang Q, Martin EC, Elliott S, Collins-Burow BM, Burow ME, Wang G. Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Research : Bcr. 14: R45. PMID 22417809 DOI: 10.1186/Bcr3144 |
0.741 |
|
| 2012 |
Tilghman SL, Bratton MR, Segar HC, Martin EC, Rhodes LV, Li M, McLachlan JA, Wiese TE, Nephew KP, Burow ME. Endocrine disruptor regulation of microRNA expression in breast carcinoma cells. Plos One. 7: e32754. PMID 22403704 DOI: 10.1371/Journal.Pone.0032754 |
0.768 |
|
| 2012 |
McLachlan JA, Tilghman SL, Burow ME, Bratton MR. Environmental signaling and reproduction: a comparative biological and chemical perspective. Molecular and Cellular Endocrinology. 354: 60-2. PMID 22178089 DOI: 10.1016/J.Mce.2011.11.028 |
0.336 |
|
| 2012 |
Wood CE, Boue SM, Collins-Burow BM, Rhodes LV, Register TC, Cline JM, Dewi FN, Burow ME. Glyceollin-elicited soy protein consumption induces distinct transcriptional effects as compared to standard soy protein. Journal of Agricultural and Food Chemistry. 60: 81-6. PMID 22126086 DOI: 10.1021/Jf2034863 |
0.666 |
|
| 2012 |
Drew BA, Burow ME, Beckman BS. MEK5/ERK5 pathway: the first fifteen years. Biochimica Et Biophysica Acta. 1825: 37-48. PMID 22020294 DOI: 10.1016/J.Bbcan.2011.10.002 |
0.439 |
|
| 2012 |
Rhodes LV, Nitschke AM, Segar HC, Martin EC, Driver JL, Elliott S, Nam SY, Li M, Nephew KP, Burow ME, Collins-Burow BM. The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells. Oncology Reports. 27: 10-6. PMID 21971930 DOI: 10.3892/Or.2011.1488 |
0.765 |
|
| 2011 |
Rhodes LV, Bratton MR, Zhu Y, Tilghman SL, Muir SE, Salvo VA, Tate CR, Elliott S, Nephew KP, Collins-Burow BM, Burow ME. Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cells. Experimental Cell Research. 317: 2573-81. PMID 21906588 DOI: 10.1016/J.Yexcr.2011.08.016 |
0.817 |
|
| 2011 |
Bareford MD, Hamed HA, Tang Y, Cruickshanks N, Burow ME, Fisher PB, Moran RG, Nephew KP, Grant S, Dent P. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Autophagy. 7: 1261-2. PMID 21814046 DOI: 10.4161/Auto.7.10.17029 |
0.414 |
|
| 2011 |
Li C, Nguyen HT, Zhuang Y, Lin Y, Flemington EK, Guo W, Guenther J, Burow ME, Morris GF, Sullivan D, Shan B. Post-transcriptional up-regulation of miR-21 by type I collagen. Molecular Carcinogenesis. 50: 563-70. PMID 21647970 DOI: 10.1002/Mc.20742 |
0.322 |
|
| 2011 |
Bareford MD, Park MA, Yacoub A, Hamed HA, Tang Y, Cruickshanks N, Eulitt P, Hubbard N, Tye G, Burow ME, Fisher PB, Moran RG, Nephew KP, Grant S, Dent P. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Research. 71: 4955-67. PMID 21622715 DOI: 10.1158/0008-5472.Can-11-0898 |
0.427 |
|
| 2011 |
Khupse RS, Sarver JG, Trendel JA, Bearss NR, Reese MD, Wiese TE, Boue SM, Burow ME, Cleveland TE, Bhatnagar D, Erhardt PW. Biomimetic syntheses and antiproliferative activities of racemic, natural (-), and unnnatural (+) glyceollin I. Journal of Medicinal Chemistry. 54: 3506-23. PMID 21513275 DOI: 10.1021/Jm101619E |
0.502 |
|
| 2011 |
Antoon JW, Meacham WD, Bratton MR, Slaughter EM, Rhodes LV, Ashe HB, Wiese TE, Burow ME, Beckman BS. Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer Journal of Molecular Endocrinology. 46: 205-216. PMID 21321095 DOI: 10.1530/Jme-10-0116 |
0.797 |
|
| 2011 |
Antoon JW, White MD, Slaughter EM, Driver JL, Khalili HS, Elliott S, Smith CD, Burow ME, Beckman BS. Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biology & Therapy. 11: 678-89. PMID 21307639 DOI: 10.4161/Cbt.11.7.14903 |
0.582 |
|
| 2011 |
Boué SM, Burow ME, Wiese TE, Shih BY, Elliott S, Carter-Wientjes CH, McLachlan JA, Bhatnagar D. Estrogenic and antiestrogenic activities of phytoalexins from red kidney bean (Phaseolus vulgaris L.). Journal of Agricultural and Food Chemistry. 59: 112-20. PMID 21133423 DOI: 10.1021/Jf102255U |
0.397 |
|
| 2011 |
Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, ... ... Burow ME, et al. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Research. 71: 603-13. PMID 21123450 DOI: 10.1158/0008-5472.Can-10-3185 |
0.81 |
|
| 2011 |
Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, Burow ME, Ivan M, Croce CM, Nephew KP. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene. 30: 1082-97. PMID 21057537 DOI: 10.1038/Onc.2010.487 |
0.476 |
|
| 2010 |
Mao L, Yuan L, Slakey LM, Jones FE, Burow ME, Hill SM. Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. Breast Cancer Research : Bcr. 12: R107. PMID 21167057 DOI: 10.1186/Bcr2794 |
0.626 |
|
| 2010 |
Rhodes LV, Antoon JW, Muir SE, Elliott S, Beckman BS, Burow ME. Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk. Molecular Cancer. 9: 295. PMID 21087507 DOI: 10.1186/1476-4598-9-295 |
0.764 |
|
| 2010 |
Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME, Jones FE. Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis. 31: 2049-57. PMID 20876285 DOI: 10.1093/Carcin/Bgq192 |
0.502 |
|
| 2010 |
Antoon JW, White MD, Meacham WD, Slaughter EM, Muir SE, Elliott S, Rhodes LV, Ashe HB, Wiese TE, Smith CD, Burow ME, Beckman BS. Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology. 151: 5124-35. PMID 20861237 DOI: 10.1210/En.2010-0420 |
0.81 |
|
| 2010 |
Jiang Q, Payton-Stewart F, Elliott S, Driver J, Rhodes LV, Zhang Q, Zheng S, Bhatnagar D, Boue SM, Collins-Burow BM, Sridhar J, Stevens C, McLachlan JA, Wiese TE, Burow ME, et al. Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells. Journal of Medicinal Chemistry. 53: 6153-63. PMID 20669983 DOI: 10.1021/Jm100610W |
0.751 |
|
| 2010 |
Bratton MR, Duong BN, Elliott S, Weldon CB, Beckman BS, McLachlan JA, Burow ME. Regulation of ERalpha-mediated transcription of Bcl-2 by PI3K-AKT crosstalk: implications for breast cancer cell survival. International Journal of Oncology. 37: 541-50. PMID 20664923 DOI: 10.3892/Ijo_00000703 |
0.527 |
|
| 2010 |
Rhodes LV, Burow ME. Human mesenchymal stem cells as mediators of breast carcinoma tumorigenesis and progression. Thescientificworldjournal. 10: 1084-7. PMID 20563531 DOI: 10.1100/Tsw.2010.108 |
0.764 |
|
| 2010 |
Payton-Stewart F, Khupse RS, Boué SM, Elliott S, Zimmermann MC, Skripnikova EV, Ashe H, Tilghman SL, Beckman BS, Cleveland TE, McLachlan JA, Bhatnagar D, Wiese TE, Erhardt P, Burow ME. Glyceollin I enantiomers distinctly regulate ER-mediated gene expression. Steroids. 75: 870-8. PMID 20493896 DOI: 10.1016/J.Steroids.2010.05.007 |
0.471 |
|
| 2010 |
Tilghman SL, Nierth-Simpson EN, Wallace R, Burow ME, McLachlan JA. Environmental hormones: Multiple pathways for response may lead to multiple disease outcomes. Steroids. 75: 520-3. PMID 20466011 DOI: 10.1016/J.Steroids.2010.05.004 |
0.391 |
|
| 2010 |
Zhuang Y, Nguyen HT, Lasky JA, Cao S, Li C, Hu J, Guo X, Burow ME, Shan B. Requirement of a novel splicing variant of human histone deacetylase 6 for TGF-beta1-mediated gene activation. Biochemical and Biophysical Research Communications. 392: 608-13. PMID 20102703 DOI: 10.1016/J.Bbrc.2010.01.091 |
0.31 |
|
| 2010 |
Struckhoff AP, Vitko JR, Rana MK, Davis CT, Foderingham KE, Liu CH, Vanhoy-Rhodes L, Elliot S, Zhu Y, Burow M, Worthylake RA. Dynamic regulation of ROCK in tumor cells controls CXCR4-driven adhesion events. Journal of Cell Science. 123: 401-12. PMID 20053635 DOI: 10.1242/Jcs.052167 |
0.432 |
|
| 2010 |
Zimmermann MC, Tilghman SL, Boué SM, Salvo VA, Elliott S, Williams KY, Skripnikova EV, Ashe H, Payton-Stewart F, Vanhoy-Rhodes L, Fonseca JP, Corbitt C, Collins-Burow BM, Howell MH, Lacey M, ... ... Burow ME, et al. Glyceollin I, a novel antiestrogenic phytoalexin isolated from activated soy. The Journal of Pharmacology and Experimental Therapeutics. 332: 35-45. PMID 19797619 DOI: 10.1124/Jpet.109.160382 |
0.467 |
|
| 2010 |
Rhodes LV, Muir SE, Elliott S, Guillot LM, Antoon JW, Penfornis P, Tilghman SL, Salvo VA, Fonseca JP, Lacey MR, Beckman BS, McLachlan JA, Rowan BG, Pochampally R, Burow ME. Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Research and Treatment. 121: 293-300. PMID 19597705 DOI: 10.1007/S10549-009-0458-2 |
0.773 |
|
| 2010 |
Hawthorne T, Gallien J, Gibbs L, Jones J, Muir S, Rhodes LV, Driver J, Khalili H, Burow M, Parker-Johnson KA. Abstract 4606: An in vitro and in vivo evaluation of novel anticancer agents in a triple negative breast cancer model Endocrinology. 70: 4606-4606. DOI: 10.1158/1538-7445.Am10-4606 |
0.765 |
|
| 2010 |
Antoon JW, White MD, Gestaut MM, Slaughter EM, Elliott S, Driver JL, Khalili HS, Smith CD, Burow ME, Beckman BS. Abstract 2537: The novel sphingosine kinase inhibitor ABC294640 blocks survival and tumorigenesis in chemo- And endocrine resistant breast cancer Cancer Research. 70: 2537-2537. DOI: 10.1158/1538-7445.Am10-2537 |
0.56 |
|
| 2010 |
White MD, Antoon JW, Meacham WD, Slaughter EM, Burow ME, Beckman BS. Abstract 1633: The sphingosine kinase inhibitor SKI-II blocks survival and MAPK signaling in human breast cancer in vitro Cancer Research. 70: 1633-1633. DOI: 10.1158/1538-7445.Am10-1633 |
0.555 |
|
| 2010 |
Gestaut MM, Antoon JW, Ponnapakam AP, J L, Burow ME, Foroozesh M, Beckman BS. Abstract 1031: Sphingolipid metabolism as a therapeutic target in chemotherapy resistant and hormone therapy resistant breast cancer Cancer Research. 70: 1031-1031. DOI: 10.1158/1538-7445.Am10-1031 |
0.525 |
|
| 2009 |
Antoon JW, Liu J, Gestaut MM, Burow ME, Beckman BS, Foroozesh M. Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells. Journal of Medicinal Chemistry. 52: 5748-52. PMID 19694470 DOI: 10.1021/Jm9009668 |
0.552 |
|
| 2009 |
Meacham WD, Antoon JW, Burow ME, Struckhoff AP, Beckman BS. Sphingolipids as determinants of apoptosis and chemoresistance in the MCF-7 cell model system. Experimental Biology and Medicine (Maywood, N.J.). 234: 1253-63. PMID 19546354 DOI: 10.3181/0902-Mr-77 |
0.563 |
|
| 2009 |
Payton-Stewart F, Schoene NW, Kim YS, Burow ME, Cleveland TE, Boue SM, Wang TT. Molecular effects of soy phytoalexin glyceollins in human prostate cancer cells LNCaP. Molecular Carcinogenesis. 48: 862-71. PMID 19263441 DOI: 10.1002/Mc.20532 |
0.419 |
|
| 2009 |
Nierth-Simpson EN, Martin MM, Chiang TC, Melnik LI, Rhodes LV, Muir SE, Burow ME, McLachlan JA. Human uterine smooth muscle and leiomyoma cells differ in their rapid 17beta-estradiol signaling: implications for proliferation. Endocrinology. 150: 2436-45. PMID 19179429 DOI: 10.1210/En.2008-0224 |
0.709 |
|
| 2009 |
Boué SM, Tilghman SL, Elliott S, Zimmerman MC, Williams KY, Payton-Stewart F, Miraflor AP, Howell MH, Shih BY, Carter-Wientjes CH, Segar C, Beckman BS, Wiese TE, Cleveland TE, McLachlan JA, ... Burow ME, et al. Identification of the potent phytoestrogen glycinol in elicited soybean (Glycine max). Endocrinology. 150: 2446-53. PMID 19116342 DOI: 10.1210/En.2008-1235 |
0.433 |
|
| 2009 |
Li Z, Carrier L, Belame A, Thiyagarajah A, Salvo VA, Burow ME, Rowan BG. Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis. Breast Cancer Research and Treatment. 118: 33-43. PMID 18855134 DOI: 10.1007/S10549-008-0216-X |
0.566 |
|
| 2009 |
Bratton MR, Frigo DE, Vigh-Conrad KA, Fan D, Wadsworth S, McLachlan JA, Burow ME. Organochlorine-mediated potentiation of the general coactivator p300 through p38 mitogen-activated protein kinase. Carcinogenesis. 30: 106-13. PMID 18791200 DOI: 10.1093/Carcin/Bgn213 |
0.321 |
|
| 2009 |
Shan B, Nguyen H, Sun L, Burow M, Palomino J, Xu R, Yao T, Lasky J. Abstract C2: Reactivation of embryonic stem cell‐like program in human cancer cells by diverse manners Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-C2 |
0.499 |
|
| 2008 |
Zhou C, Nitschke AM, Xiong W, Zhang Q, Tang Y, Bloch M, Elliott S, Zhu Y, Bazzone L, Yu D, Weldon CB, Schiff R, McLachlan JA, Beckman BS, Wiese TE, ... ... Burow ME, et al. Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Research : Bcr. 10: R105. PMID 19087274 DOI: 10.1186/Bcr2210 |
0.519 |
|
| 2008 |
Dimple C, Nair SS, Rajhans R, Pitcheswara PR, Liu J, Balasenthil S, Le XF, Burow ME, Auersperg N, Tekmal RR, Broaddus RR, Vadlamudi RK. Role of PELP1/MNAR signaling in ovarian tumorigenesis. Cancer Research. 68: 4902-9. PMID 18559538 DOI: 10.1158/0008-5472.Can-07-5698 |
0.489 |
|
| 2008 |
Fox JE, Burow ME, McLachlan JA, Miller CA. Detecting ligands and dissecting nuclear receptor-signaling pathways using recombinant strains of the yeast Saccharomyces cerevisiae. Nature Protocols. 3: 637-45. PMID 18388946 DOI: 10.1038/Nprot.2008.33 |
0.309 |
|
| 2007 |
Tang Y, Zhao DY, Elliott S, Zhao W, Curiel TJ, Beckman BS, Burow ME. Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression. International Journal of Oncology. 31: 705-11. PMID 17786300 DOI: 10.3892/Ijo.31.4.705 |
0.542 |
|
| 2007 |
Lacey MR, Brumlik MJ, Yenni RE, Burow ME, Curiel TJ. Toxoplasma gondii expresses two mitogen-activated protein kinase genes that represent distinct protozoan subfamilies. Journal of Molecular Evolution. 64: 4-14. PMID 17160647 DOI: 10.1007/S00239-005-0197-X |
0.33 |
|
| 2006 |
Wood CE, Clarkson TB, Appt SE, Franke AA, Boue SM, Burow ME, McCoy T, Cline JM. Effects of soybean glyceollins and estradiol in postmenopausal female monkeys. Nutrition and Cancer. 56: 74-81. PMID 17176220 DOI: 10.1207/S15327914Nc5601_10 |
0.454 |
|
| 2006 |
Salvo VA, Boué SM, Fonseca JP, Elliott S, Corbitt C, Collins-Burow BM, Curiel TJ, Srivastav SK, Shih BY, Carter-Wientjes C, Wood CE, Erhardt PW, Beckman BS, McLachlan JA, Cleveland TE, ... Burow ME, et al. Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 7159-64. PMID 17145841 DOI: 10.1158/1078-0432.Ccr-06-1426 |
0.523 |
|
| 2006 |
Duong BN, Elliott S, Frigo DE, Melnik LI, Vanhoy L, Tomchuck S, Lebeau HP, David O, Beckman BS, Alam J, Bratton MR, McLachlan JA, Burow ME. AKT regulation of estrogen receptor beta transcriptional activity in breast cancer. Cancer Research. 66: 8373-81. PMID 16951146 DOI: 10.1158/0008-5472.Can-05-3845 |
0.497 |
|
| 2006 |
Frigo DE, Basu A, Nierth-Simpson EN, Weldon CB, Dugan CM, Elliott S, Collins-Burow BM, Salvo VA, Zhu Y, Melnik LI, Lopez GN, Kushner PJ, Curiel TJ, Rowan BG, McLachlan JA, ... Burow ME, et al. p38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1. Molecular Endocrinology (Baltimore, Md.). 20: 971-83. PMID 16410316 DOI: 10.1210/Me.2004-0075 |
0.402 |
|
| 2005 |
Hardman MJ, Waite A, Zeef L, Burow M, Nakayama T, Ashcroft GS. Macrophage migration inhibitory factor: a central regulator of wound healing. The American Journal of Pathology. 167: 1561-74. PMID 16314470 DOI: 10.1016/S0002-9440(10)61241-2 |
0.338 |
|
| 2005 |
Kiefer TL, Lai L, Yuan L, Dong C, Burow ME, Hill SM. Differential regulation of estrogen receptor alpha, glucocorticoid receptor and retinoic acid receptor alpha transcriptional activity by melatonin is mediated via different G proteins. Journal of Pineal Research. 38: 231-9. PMID 15813899 DOI: 10.1111/J.1600-079X.2004.00198.X |
0.423 |
|
| 2005 |
Weldon CB, McKee A, Collins-Burow BM, Melnik LI, Scandurro AB, McLachlan JA, Burow ME, Beckman BS. PKC-mediated survival signaling in breast carcinoma cells: a role for MEK1-AP1 signaling. International Journal of Oncology. 26: 763-8. PMID 15703835 DOI: 10.3892/Ijo.26.3.763 |
0.454 |
|
| 2005 |
Frigo DE, Vigh KA, Struckhoff AP, Elliott S, Beckman BS, Burow ME, McLachlan JA. Xenobiotic-induced TNF-alpha expression and apoptosis through the p38 MAPK signaling pathway. Toxicology Letters. 155: 227-38. PMID 15603917 DOI: 10.1016/J.Toxlet.2004.09.008 |
0.392 |
|
| 2004 |
Williams CC, Allison JG, Vidal GA, Burow ME, Beckman BS, Marrero L, Jones FE. The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. The Journal of Cell Biology. 167: 469-78. PMID 15534001 DOI: 10.1083/Jcb.200403155 |
0.481 |
|
| 2004 |
Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine. 10: 942-9. PMID 15322536 DOI: 10.1038/Nm1093 |
0.339 |
|
| 2004 |
Weldon CB, Elliott S, Zhu Y, Clayton JL, Curiel TJ, Jaffe BM, Burow ME. Regulation of estrogen-mediated cell survival and proliferation by p160 coactivators. Surgery. 136: 346-54. PMID 15300201 DOI: 10.1016/J.Surg.2004.05.010 |
0.546 |
|
| 2004 |
Weldon CB, Parker AP, Patten D, Elliott S, Tang Y, Frigo DE, Dugan CM, Coakley EL, Butler NN, Clayton JL, Alam J, Curiel TJ, Beckman BS, Jaffe BM, Burow ME. Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling. International Journal of Oncology. 24: 1473-80. PMID 15138590 DOI: 10.3892/Ijo.24.6.1473 |
0.465 |
|
| 2004 |
Fox JE, Starcevic M, Jones PE, Burow ME, McLachlan JA. Phytoestrogen signaling and symbiotic gene activation are disrupted by endocrine-disrupting chemicals. Environmental Health Perspectives. 112: 672-7. PMID 15121509 DOI: 10.1289/Ehp.6456 |
0.31 |
|
| 2004 |
Struckhoff AP, Bittman R, Burow ME, Clejan S, Elliott S, Hammond T, Tang Y, Beckman BS. Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. The Journal of Pharmacology and Experimental Therapeutics. 309: 523-32. PMID 14742741 DOI: 10.1124/Jpet.103.062760 |
0.565 |
|
| 2004 |
Frigo DE, Tang Y, Beckman BS, Scandurro AB, Alam J, Burow ME, McLachlan JA. Mechanism of AP-1-mediated gene expression by select organochlorines through the p38 MAPK pathway. Carcinogenesis. 25: 249-61. PMID 14604893 DOI: 10.1093/Carcin/Bgh009 |
0.38 |
|
| 2003 |
Simstein R, Burow M, Parker A, Weldon C, Beckman B. Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Experimental Biology and Medicine (Maywood, N.J.). 228: 995-1003. PMID 14530507 DOI: 10.1177/153537020322800903 |
0.581 |
|
| 2003 |
Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, David O, Burow M, Gordon A, Dhurandhar N, Myers L, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nature Medicine. 9: 562-7. PMID 12704383 DOI: 10.1038/Nm863 |
0.336 |
|
| 2003 |
Boué SM, Wiese TE, Nehls S, Burow ME, Elliott S, Carter-Wientjes CH, Shih BY, McLachlan JA, Cleveland TE. Evaluation of the estrogenic effects of legume extracts containing phytoestrogens. Journal of Agricultural and Food Chemistry. 51: 2193-9. PMID 12670155 DOI: 10.1021/Jf021114S |
0.388 |
|
| 2002 |
Figueroa YG, Chan AK, Ibrahim R, Tang Y, Burow ME, Alam J, Scandurro AB, Beckman BS. NF-kappaB plays a key role in hypoxia-inducible factor-1-regulated erythropoietin gene expression. Experimental Hematology. 30: 1419-27. PMID 12482504 DOI: 10.1016/S0301-472X(02)00934-7 |
0.317 |
|
| 2002 |
Frigo DE, Burow ME, Mitchell KA, Chiang TC, McLachlan JA. DDT and its metabolites alter gene expression in human uterine cell lines through estrogen receptor-independent mechanisms. Environmental Health Perspectives. 110: 1239-45. PMID 12460804 DOI: 10.1289/Ehp.021101239 |
0.424 |
|
| 2002 |
Weldon CB, Scandurro AB, Rolfe KW, Clayton JL, Elliott S, Butler NN, Melnik LI, Alam J, McLachlan JA, Jaffe BM, Beckman BS, Burow ME. Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray. Surgery. 132: 293-301. PMID 12219026 DOI: 10.1067/Msy.2002.125389 |
0.33 |
|
| 2002 |
Frigo DE, Duong BN, Melnik LI, Schief LS, Collins-Burow BM, Pace DK, McLachlan JA, Burow ME. Flavonoid phytochemicals regulate activator protein-1 signal transduction pathways in endometrial and kidney stable cell lines. The Journal of Nutrition. 132: 1848-53. PMID 12097658 DOI: 10.1093/Jn/132.7.1848 |
0.409 |
|
| 2001 |
Fox JE, Burow ME, McLachlan JA. Symbiotic gene activation is interrupted by endocrine disrupting chemicals. Thescientificworldjournal. 1: 653-5. PMID 12805768 DOI: 10.1100/Tsw.2001.359 |
0.454 |
|
| 2001 |
Burow ME, Weldon CB, Tang Y, McLachlan JA, Beckman BS. Oestrogen-mediated suppression of tumour necrosis factor alpha-induced apoptosis in MCF-7 cells: subversion of Bcl-2 by anti-oestrogens. The Journal of Steroid Biochemistry and Molecular Biology. 78: 409-18. PMID 11738551 DOI: 10.1016/S0960-0760(01)00117-0 |
0.456 |
|
| 2001 |
Gulledge CC, Burow ME, McLachlan JA. Endocrine disruption in sexual differentiation and puberty: What do pseudohermaphroditic polar bears have to do with the practice of pediatrics? Pediatric Clinics of North America. 48: 1223-1240. PMID 11579671 DOI: 10.1016/S0031-3955(05)70371-0 |
0.395 |
|
| 2001 |
Fox JE, Starcevic M, Kow KY, Burow ME, McLachlan JA. Nitrogen fixation. Endocrine disrupters and flavonoid signalling. Nature. 413: 128-9. PMID 11557969 DOI: 10.1038/35093163 |
0.313 |
|
| 2001 |
Weldon CB, Burow ME, Rolfe KW, Clayton JL, Jaffe BM, Beckman BS. NF-κB-mediated chemoresistance in breast cancer cells Surgery. 130: 143-150. PMID 11490342 DOI: 10.1067/Msy.2001.115512 |
0.445 |
|
| 2001 |
McLachlan JA, Newbold RR, Burow ME, Li SF. From malformations to molecular mechanisms in the male: Three decades of research on endocrine disrupters Apmis. 109: 263-272. PMID 11469497 DOI: 10.1034/J.1600-0463.2001.D01-119.X |
0.319 |
|
| 2001 |
O'Neil JS, Burow ME, Green AE, McLachlan JA, Henson MC. Effects of estrogen on leptin gene promoter activation in MCF-7 breast cancer and JEG-3 choriocarcinoma cells: selective regulation via estrogen receptors alpha and beta. Molecular and Cellular Endocrinology. 176: 67-75. PMID 11369444 DOI: 10.1016/S0303-7207(01)00473-7 |
0.523 |
|
| 2001 |
Burow ME, Boue SM, Collins-Burow BM, Melnik LI, Duong BN, Carter-Wientjes CH, Li S, Wiese TE, Cleveland TE, McLachlan JA. Phytochemical glyceollins, isolated from soy, mediate antihormonal effects through estrogen receptor alpha and beta. The Journal of Clinical Endocrinology and Metabolism. 86: 1750-8. PMID 11297613 DOI: 10.1210/Jcem.86.4.7430 |
0.37 |
|
| 2000 |
Collins-Burow BM, Burow ME, Duong BN, McLachlan JA. Estrogenic and antiestrogenic activities of flavonoid phytochemicals through estrogen receptor binding-dependent and -independent mechanisms. Nutrition and Cancer. 38: 229-44. PMID 11525602 DOI: 10.1207/S15327914Nc382_13 |
0.498 |
|
| 2000 |
Alam J, Wicks C, Stewart D, Gong P, Touchard C, Otterbein S, Choi AM, Burow ME, Tou J. Mechanism of heme oxygenase-1 gene activation by cadmium in MCF-7 mammary epithelial cells. Role of p38 kinase and Nrf2 transcription factor. The Journal of Biological Chemistry. 275: 27694-702. PMID 10874044 DOI: 10.1074/Jbc.M004729200 |
0.371 |
|
| 2000 |
Burow ME, Weldon CB, Chiang TC, Tang Y, Collins-Burow BM, Rolfe K, Li S, McLachlan JA, Beckman BS. Differences in protein kinase C and estrogen receptor alpha, beta expression and signaling correlate with apoptotic sensitivity of MCF-7 breast cancer cell variants. International Journal of Oncology. 16: 1179-87. PMID 10811993 DOI: 10.3892/Ijo.16.6.1179 |
0.517 |
|
| 2000 |
Burow ME, Weldon CB, Melnik LI, Duong BN, Collins-Burow BM, Beckman BS, McLachlan JA. PI3-K/AKT regulation of NF-kappaB signaling events in suppression of TNF-induced apoptosis. Biochemical and Biophysical Research Communications. 271: 342-5. PMID 10799299 DOI: 10.1006/Bbrc.2000.2626 |
0.399 |
|
| 2000 |
Burow ME, Weldon CB, Collins-Burow BM, Ramsey N, McKee A, Klippel A, McLachlan JA, Clejan S, Beckman BS. Cross-talk between phosphatidylinositol 3-kinase and sphingomyelinase pathways as a mechanism for cell survival/death decisions. The Journal of Biological Chemistry. 275: 9628-35. PMID 10734114 DOI: 10.1074/Jbc.275.13.9628 |
0.391 |
|
| 1999 |
Jolibois LS, Burow ME, Swan KF, George WJ, Anderson MB, Henson MC. Effects of cadmium cell viability, trophoblastic development, and expression of low density lipoprotein receptor transcripts in cultured human placental cells. Reproductive Toxicology (Elmsford, N.Y.). 13: 473-80. PMID 10613395 DOI: 10.1016/S0890-6238(99)00041-6 |
0.343 |
|
| 1999 |
Burow ME, Tang Y, Collins-Burow BM, Krajewski S, Reed JC, McLachlan JA, Beckman BS. Effects of environmental estrogens on tumor necrosis factor alpha-mediated apoptosis in MCF-7 cells. Carcinogenesis. 20: 2057-61. PMID 10545406 DOI: 10.1093/Carcin/20.11.2057 |
0.447 |
|
| Show low-probability matches. |